Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
तुलना करने के लिए मीट्रिक्स | DAWN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधDAWNपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −7.7x | −2.1x | −0.5x | |
PEG अनुपात | 0.14 | −0.04 | 0.00 | |
क़ीमत/बुक | 2.6x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 8.7x | 184.4x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 106.4% | 154.3% | 47.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 14.1% | 5.7% | अनलॉक करें |